Haegarda FDA Approval History
FDA Approved: Yes (First approved June 22, 2017)
Brand name: Haegarda
Generic name: C1 esterase inhibitor (human)
Dosage form: Subcutaneous Injection
Previous Name: CSL830
Company: CSL Behring
Treatment for: Hereditary Angioedema
Haegarda (C1 esterase inhibitor (human)) is a low-volume subcutaneous (SC) C1-esterase inhibitor (C1-INH) replacement therapy to prevent Hereditary Angioedema (HAE) attacks.
Development Timeline for Haegarda
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.